Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study [PDF]
International Journal of Infectious Diseases, 2021 Objective: The aim of this study was to evaluate the efficacy of anakinra in patients who were admitted to hospital for severe COVID-19 pneumonia requiring oxygen therapy.
A. Balkhair +31 more
doaj +2 more sources
Clinical outcomes and safety of anakinra in the treatment of multisystem inflammatory syndrome in children: a single center observational study [PDF]
Pediatric Rheumatology Online Journal, 2023 Background and objective Evidence for the treatment of multisystem inflammatory syndrome in children (MIS-C) is lacking. Anakinra, which targets IL-1-mediated inflammation, is reserved for refractory cases of MIS-C; however, its use in the treatment of ...
Brian L.P. Dizon +13 more
doaj +2 more sources
The Effect of Anakinra on Acrylamide-induced Peripheral Neuropathy and Neuropathic Pain in Rats
Brazilian Journal of Pharmaceutical Sciences, 2023 Acrylamide is a neurotoxic compound. Moreover, anakinra is an interleukin-1 (IL-1) receptor antagonist used in rheumatoid arthritis treatment. This study investigated the effect of anakinra on acrylamide-related neuropathy and neuropathic pain ...
Alevtina Ersoy +5 more
doaj +2 more sources
Anakinra Removal by Continuous Renal Replacement Therapy: An Ex Vivo Analysis
Critical Care Explorations, 2023 OBJECTIVES:. Patients with sepsis are at significant risk for multiple organ dysfunction, including the lungs and kidneys. To manage the morbidity associated with kidney impairment, continuous renal replacement therapy (CRRT) may be required.
Samuel D.J. Dubinsky, PharmD +7 more
doaj +2 more sources
PLoS ONE, 2022 ObjectiveWe aimed to investigate whether anakinra, an interleukin-1receptor inhibitor, could improve outcome in moderate COVID-19 patients.MethodsIn this controlled, open-label trial, we enrolled adults with COVID-19 requiring oxygen.
Alexandra Audemard-Verger +29 more
doaj +3 more sources
Treatment of cytokine storm syndrome with IL‐1 receptor antagonist anakinra in a patient with ARDS caused by COVID‐19 infection: A case report [PDF]
Clinical Case Reports, 2020 The biological anakinra appears promising to halt cytokine storm syndrome seen in severe courses of COVID‐19. However, immunosuppression with anakinra may facilitate sepsis, necessitating continuous screening for bacterial superinfections.
Leonard Kaps +5 more
doaj +2 more sources
Efficacy of Anakinra for Various Types of Crystal-Induced Arthritis in Complex Hospitalized Patients: A Case Series and Review of the Literature [PDF]
Mediators of Inflammation, 2015 Background. There are few data on anakinra use after failure of conventional medications for crystal-induced peripheral arthritis and/or crowned dens syndrome among complex hospitalized patients. Methods.
A. Aouba +9 more
doaj +7 more sources
Efficacy and Safety of Anakinra in Colchicine-Resistant or -Intolerant Familial Mediterranean Fever: A Single-Center Real-Life Experience [PDF]
MedicinaFamilial Mediterranean Fever (FMF) is characterized by recurrent febrile attacks and serositis. While colchicine is the primary treatment for FMF, some patients present resistance or intolerance with respect to this drug.
Tuğba Ocak +5 more
doaj +2 more sources
Protective Effects of Interleukin-1 Inhibition With Anakinra in Mouse Models of Ischemic Stroke With and Without Reperfusion. [PDF]
J Am Heart AssocChaparro-Cabanillas N +11 more
europepmc +2 more sources
The Endogenous Th17 Response in NO
, 2013 Severe, glucocorticoid-resistant asthma comprises 5-7% of patients with asthma. IL-17 is a biomarker of severe asthma, and the adoptive transfer of Th17 cells in mice is sufficient to induce glucocorticoid-resistant allergic airway disease.
A Abe +106 more
core +17 more sources